Topotecan Plus Apatinib Versus Topotecan Alone as Second-line Therapy in Small-cell Lung Cancer

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2017
The purpose of this study is to determine whether topotecan plus apatinib are superior to topotecan alone as second-line therapy in small-cell lung cancer.
Epistemonikos ID: d16a5340fffabc818af739422e7322087070136f
First added on: May 20, 2024